PRE
Prenetics Global Limited
$20.17
-1.78
(-8.11%)
Mkt Cap
342.90M
Volume
311,504
52W Range
11.365-27.24
Sector
Consumer Defensive
Beta
0.25
EPS (TTM)
-4.16 USD
P/E Ratio
-5.88
Revenue (TTM)
142.56M USD
Rev Growth (5Y)
+7.2%
EPS Growth (5Y)
N/A
Company Description
Prenetics Global Limited is a consumer health sciences company that has pivoted to focus on a consumer health and longevity platform. The company's main brand is IM8, which offers science-backed nutritional supplements. It also operates CircleDNA, a consumer genetic testing brand that provides personalized health reports based on sequencing technology.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 92.39M | 30.62M | 21.74M | 13.16M | 12.53M | 65.18M | 9.23M |
| Net Income | (37.71M) | (46.30M) | (62.72M) | (190.45M) | (174.01M) | (1.94M) | (20.14M) |
| EPS | -2.68 | -3.64 | -5.58 | -37.57 | -47.04 | -0.26 | -2.73 |
| Free Cash Flow | (22.02M) | (29.94M) | (14.68M) | 8.17M | 2.00M | (5.94M) | (2.26M) |
| FCF / Share | -1.57 | -2.36 | -1.31 | 1.61 | 0.54 | -0.80 | -0.31 |
| Operating CF | (21.81M) | (28.87M) | (13.76M) | 14.51M | 13.42M | (2.88M) | (1.88M) |
| Total Assets | 203.52M | 213.57M | 254.17M | 312.13M | 148.51M | 78.88M | 29.69M |
| Total Debt | 2.20M | 5.77M | 2.37M | 6.65M | 491.67M | 17.14M | 1.46M |
| Cash & Equiv | 32.13M | 52.25M | 45.71M | 146.66M | 35.29M | 14.49M | 11.52M |
| Book Value | 174.60M | 170.39M | 206.36M | 237.06M | (400.81M) | 31.08M | 16.91M |
| Return on Equity | -0.22 | -0.27 | -0.30 | -0.80 | N/A | -0.06 | -1.19 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.49M | 35.95M | 36.56M | 23.55M | 17.68M | 17.31M | 10.49M | 7.78M | 5.94M | 6.41M | 5.28M | 4.88M |
| Net Income | (8.98M) | (23.10M) | (28.11M) | (7.41M) | (12.41M) | (10.39M) | (16.34M) | (10.67M) | (10.72M) | (8.57M) | (16.95M) | (13.57M) |
| EPS | -0.52 | -1.36 | -1.75 | -0.53 | -0.94 | -0.80 | -1.29 | -0.84 | -0.88 | -0.70 | -1.40 | -1.16 |
| Free Cash Flow | 0 | (12.12M) | (22.02M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FCF / Share | N/A | -0.71 | -1.37 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating CF | (15.45M) | (12.12M) | (21.81M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 153.66M | 175.30M | 203.52M | 196.51M | 199.11M | 204.01M | 213.57M | 235.77M | 233.31M | 243.59M | 254.17M | 276.41M |
| Total Debt | 682,000 | 457,000 | 2.20M | 2.10M | 2.57M | 5.15M | 5.77M | 6.49M | 2.36M | 1.75M | 2.37M | 5.26M |
| Cash & Equiv | 59.05M | 56.02M | 32.13M | 13.26M | 17.25M | 47.97M | 52.25M | 31.94M | 41.20M | 54.52M | 45.71M | 71.25M |
| Book Value | 93.01M | 121.11M | 174.60M | 161.29M | 150.98M | 160.88M | 170.39M | 178.68M | 188.24M | 199.44M | 206.36M | 224.44M |
| Return on Equity | -0.10 | -0.19 | -0.16 | -0.05 | -0.08 | -0.06 | -0.10 | -0.06 | -0.06 | -0.04 | -0.08 | -0.06 |
PRE News
U.S. VEHICLE SALES UNLIKELY TO REGAIN PRE-PANDEMIC LEVELS THIS DECADE, MOBILITY GLOBAL FORECAST SHOWS
Prenetics Global Limited (NASDAQ:PRE) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Prenetics' IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results
Prenetics Global: Marketing Mastery The Key To Robust Revenue Growth
Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript
Prenetics' IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
Prenetics Global Q2 Earnings Call Highlights
Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Consolidated Adjusted Free Cash Flow and Expected to Remain Positive for Q3 and Beyond
Prenetics, Parent of IM8, Appoints II Ranked, Caroline Levy, Veteran Wall Street Consumer Analyst as Independent Director
Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation